FN1 and cancer: Future studies and novel labelling approaches, such as the recently described dual-antibody-staining technique59, are needed to investigate whether Fn fibrils are indeed more relaxed in actual cancer stroma tissue, in which it is very challenging to incorporate FRET-labelled Fn.